Biogen Inc. (BIIB)

226.84
94.00 29.00
NASDAQ : Health Technology
Prev Close 320.59
Open 230.07
Day Low/High 224.60 / 235.77
52 Wk Low/High 249.17 / 388.67
Volume 21.55M
Avg Volume 1.30M
Exchange NASDAQ
Shares Outstanding 196.71M
Market Cap 63.69B
EPS 21.60
P/E Ratio 15.00
Div & Yield N.A. (N.A)
Biogen To Present At The Guggenheim 5th Annual Healthcare Conference

Biogen To Present At The Guggenheim 5th Annual Healthcare Conference

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Guggenheim 5 th Annual Healthcare Conference.

Biogen Appoints Mark Hernon As SVP, Chief Information Officer

Biogen Appoints Mark Hernon As SVP, Chief Information Officer

Biogen (NASDAQ: BIIB) announced today the appointment of Mark Hernon as Senior Vice President, Chief Information Officer, effective December 4.

Biogen Moves Up In Analyst Rankings, Passing Kraft Heinz

Biogen Moves Up In Analyst Rankings, Passing Kraft Heinz

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Biogen Inc has taken over the #96 spot from Kraft Heinz Co , according to ETF Channel. Below is a chart of Biogen Inc versus Kraft Heinz Co plotting their respective rank within the S&P 500 over time (BIIB plotted in blue; KHC plotted in green): In forming the rank, the analyst opinions from the major brokerage houses were tallied, and averaged; then, the underlying components were ranked according to those averages.

Alkermes Jumps on License Deal With Biogen -- Biotech Movers

Alkermes Jumps on License Deal With Biogen -- Biotech Movers

Alkermes and Biogen have inked a pact to develop and commercialize ALKS 8700, which is in Phase 3 development for treating relapsing forms of multiple sclerosis.

Http://www.alkermes.com/

Http://www.alkermes.com/

Biogen (Nasdaq:BIIB) and Alkermes plc (Nasdaq:ALKS) today announced that they have entered into a global license and collaboration agreement to develop and commercialize ALKS 8700, a novel, oral, monomethyl...

Biogen And Alkermes Announce License And Collaboration Agreement To Develop And Commercialize ALKS 8700 For The Treatment Of Multiple Sclerosis

Biogen And Alkermes Announce License And Collaboration Agreement To Develop And Commercialize ALKS 8700 For The Treatment Of Multiple Sclerosis

Biogen (Nasdaq:BIIB) and Alkermes plc (Nasdaq:ALKS) today announced that they have entered into a global license and collaboration agreement to develop and commercialize ALKS 8700, a novel, oral, monomethyl...

Biogen Appoints Jeff Capello As Executive Vice President And Chief Financial Officer

Biogen Appoints Jeff Capello As Executive Vice President And Chief Financial Officer

Biogen (Nasdaq: BIIB) announced today the appointment of Jeffrey D.

Biogen To Present At The Evercore ISI Biopharma Catalyst/Deep Dive Conference

Biogen To Present At The Evercore ISI Biopharma Catalyst/Deep Dive Conference

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference.

Biogen Appoints Chirfi Guindo As Executive Vice President And Head Of Global Marketing, Market Access And Customer Innovation

Biogen Appoints Chirfi Guindo As Executive Vice President And Head Of Global Marketing, Market Access And Customer Innovation

Biogen (Nasdaq: BIIB) announced today the appointment of Chirfi Guindo as Executive Vice President and Head of Global Marketing, Market Access and Customer Innovation.

Biogen Presents New Data From Long-Term Extension Of Phase 1b Study Of Investigational Alzheimer's Disease Treatment Aducanumab

Biogen Presents New Data From Long-Term Extension Of Phase 1b Study Of Investigational Alzheimer's Disease Treatment Aducanumab

Biogen (NASDAQ: BIIB) will present new data from the long-term extension (LTE) of its ongoing Phase 1b study of aducanumab, the company's investigational treatment for Alzheimer's disease, at the Clinical Trials on...

The New England Journal Of Medicine Publishes First Phase 3 Study Results Of SPINRAZA® For The Treatment Of Spinal Muscular Atrophy

The New England Journal Of Medicine Publishes First Phase 3 Study Results Of SPINRAZA® For The Treatment Of Spinal Muscular Atrophy

Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that the end of study results from ENDEAR, the Phase 3 study of SPINRAZA ® (nusinersen) for the treatment of spinal muscular atrophy...

Biogen To Present At The Clinical Trials On Alzheimer's Disease Conference

Biogen To Present At The Clinical Trials On Alzheimer's Disease Conference

Biogen Inc. (NASDAQ: BIIB) announced today that it will present detailed data from a recently conducted analysis of the long-term extension of its ongoing Phase 1b study of aducanumab at the 10 th Clinical Trials on...

Biogen And Ionis Win Prestigious Prix Galien Award For SPINRAZA As Best Biotechnology Product

Biogen And Ionis Win Prestigious Prix Galien Award For SPINRAZA As Best Biotechnology Product

Biogen (NASDAQ: BIIB) and Ionis have been awarded the prestigious 2017 Prix Galien USA Award for Best Biotechnology Product for SPINRAZA® (nusinersen).

Celgene's Stock Is Getting Absolutely Torched -- Don't Panic, Yet

Celgene's Stock Is Getting Absolutely Torched -- Don't Panic, Yet

Shares of Celgene are down more than 30% so far this month and almost 20% Thursday as the company cuts full-year and 2020 guidance.

Venator Materials, Biogen Idec, Corning: 'Mad Money' Lightning Round

Venator Materials, Biogen Idec, Corning: 'Mad Money' Lightning Round

Jim Cramer is bullish on Venator Materials, Biogen Idec, Corning.

Good Stocks on Sale: Cramer's 'Mad Money' Recap (Wednesday 10/25/17)

Good Stocks on Sale: Cramer's 'Mad Money' Recap (Wednesday 10/25/17)

Jim Cramer has a special set of rules for what to buy and where to take a pass.

Biogen Announces AFFINITY Phase 2 Trial Initiation For Opicinumab (Anti-LINGO-1) In Multiple Sclerosis

Biogen Announces AFFINITY Phase 2 Trial Initiation For Opicinumab (Anti-LINGO-1) In Multiple Sclerosis

Biogen (NASDAQ: BIIB) announced today the recent initiation of the Phase 2 clinical trial AFFINITY, designed to evaluate opicinumab as an investigational add-on therapy in people with relapsing multiple sclerosis...

Closing Bell: Stocks Surge on Strong Earnings Reports Across the Board

Closing Bell: Stocks Surge on Strong Earnings Reports Across the Board

Stocks closed confidently higher Tuesday.

Biogen Shares Hit After Poor U.S. Sales for Muscular Atrophy Treatment

Biogen Shares Hit After Poor U.S. Sales for Muscular Atrophy Treatment

During the third quarter, U.S. sales of Biogen's spinal muscular atrophy treatment Spinraza totaled $198M, compared with consensus of $212M.

Positive Earnings Drive Dow to New Record in Best Performance in a Month

Positive Earnings Drive Dow to New Record in Best Performance in a Month

Powerhouse performances from Caterpillar and 3M inspire a Dow rally, leading the index to new all-time highs in its 54th record close of the year.

Dow Rises 200 Points With Records in Grasp After Caterpillar, 3M Earnings

Dow Rises 200 Points With Records in Grasp After Caterpillar, 3M Earnings

Better-than-expected earnings from a number of key Dow components sweep markets higher.

Caterpillar, McDonald's and 3M Earnings Fuel Stock Rebound

Caterpillar, McDonald's and 3M Earnings Fuel Stock Rebound

Strong earnings from Dow components Caterpillar, McDonald's and 3M were on track to push the blue-chip index higher after a 0.23% decline on Monday.

McDonald's, Sears and Amazon - 5 Things You Must Know Before the Market Opens

McDonald's, Sears and Amazon - 5 Things You Must Know Before the Market Opens

U.S. stock futures are rising on Tuesday, after Wall Street's record-breaking streak came to an end during the previous trading session.

Biogen Reports Quarterly Revenues Of $3.1 Billion

Biogen Reports Quarterly Revenues Of $3.1 Billion

Biogen Inc. (NASDAQ: BIIB) today reported third quarter 2017 financial results, including: Total revenues of $3.

Biogen Increases Profit Potential On Investigational Alzheimer's Disease Treatment Aducanumab Through Amended Agreement With Neurimmune Holding AG

Biogen Increases Profit Potential On Investigational Alzheimer's Disease Treatment Aducanumab Through Amended Agreement With Neurimmune Holding AG

Biogen (NASDAQ: BIIB) announced today that it has increased the profit potential on aducanumab, its Phase 3 investigational treatment for early Alzheimer's disease, by reducing the potential royalty payment on potential...

Futures and Dollar Rise as Trump Narrows Down Pool for Next Fed Chair

Futures and Dollar Rise as Trump Narrows Down Pool for Next Fed Chair

A decision should be made 'in the coming days.'

Third-Quarter U.S. Economic Growth to Reveal Hurricane Damage in Week Ahead

Third-Quarter U.S. Economic Growth to Reveal Hurricane Damage in Week Ahead

A string of severe hurricanes that swept across the south and southeastern portions of the U.S. and Puerto Rico toward the end of the third quarter could put a big dent in economic growth.

Biogen Confirms Commitment To Tackle Multiple Sclerosis Through Comprehensive Approach

Biogen Confirms Commitment To Tackle Multiple Sclerosis Through Comprehensive Approach

Biogen (NASDAQ: BIIB) confirms its comprehensive approach to tackle multiple sclerosis (MS) at the seventh Joint Meeting of the European Committee for Treatment and Research in MS and Americas Committee for Treatment...

UnitedHealth and a Bipartisan Healthcare Deal Send Dow, S&P 500 to Records

UnitedHealth and a Bipartisan Healthcare Deal Send Dow, S&P 500 to Records

A flood of earnings from the likes of UnitedHealth, Johnson & Johnson and Goldman Sachs keeps investors occupied on Tuesday.

TheStreet Quant Rating: B (Buy)